# LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

> **NCT01041040** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 200 (actual)

## Conditions studied

- Acute Myeloblastic Leukemia

## Interventions

- **DRUG:** gemtuzumab

## Key facts

- **NCT ID:** NCT01041040
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2013-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01041040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01041040, "LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01041040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*